<![CDATA[Hemoperfusion is feasible and safe in healthy goats, Texas A&M study finds]]>

Research Briefs

Hemoperfusion proves feasible and safe in healthy goats, Texas A&M study finds

A Texas A&M and Cornell prospective trial found polymer and carbon hemoperfusion columns safe in healthy goats, though heparin needs ran double those of horses.

Photo: stevepb / pixabay

Hemoperfusion using adsorbent filter columns caused no serious adverse events in healthy adult goats, and the technique cleared a key safety hurdle for a species with limited options in toxicosis and sepsis, according to a prospective experimental study from Texas A&M and Cornell published in the American Journal of Veterinary Research.

Researchers at the Texas A&M College of Veterinary Medicine & Biomedical Sciences and the Cornell University College of Veterinary Medicine tested two columns: the polymer-based VetResQ (CytoSorbents Inc) and the activated carbon Cytoclear (AimaLojic). The trial ran between April and September 2025 on healthy adult goats from the Texas A&M research herd.

"Hemoperfusion using both polymer-based and carbon-based adsorptive columns is feasible and appears safe in goats, although higher heparin doses are required compared to other species," the investigators concluded.

Why goats need faster toxin removal

More goats are entering the pet population, and the species tends to consume harmful substances, including toxic plants and trace mineral–rich feed formulated for cattle and horses, the authors wrote. Conventional treatments may fall short.

"[C]onventional treatments, such as activated charcoal, lipid emulsion, fluid therapy, antimicrobials, and supportive care, may be insufficient, specifically in cases where access to treatment is delayed and rapid removal of circulating toxins or inflammatory mediators is critical for survival," the paper stated.

Kallie Hobbs, DVM, PhD, DACVIM, assistant professor in the VMBS Department of Large Animal Clinical Sciences and the study's corresponding author, pointed to a common household risk. "If a goat gets into Advil or something similar, it can become a problem," she said in a Texas A&M news release.

What happened during treatment?

Veterinarians placed a jugular catheter without sedation. Four goats completed the targeted two blood volumes of treatment, each session taking 60 to 90 minutes. One session stopped after a single blood volume because of equipment failure.

No jugular vein thrombosis, abnormal bleeding, or altered cardiovascular status occurred. Physical examination parameters stayed within normal ranges, and the goats stood tied and ate hay throughout the procedure.

Hematology and biochemistry values remained within reference ranges. The takeaway: both column types were tolerated clinically.

Protein loss and cytokine findings

Total protein and albumin declined during filtration and only partially recovered by 24 hours. The authors said this suggests goats with protein-losing conditions may require added monitoring during hemoperfusion.

Interleukin-1β and tumor necrosis factor–α decreased after treatment in all goats, although the cytokine data were not statistically analyzed. The plain meaning: the filters did not trigger inflammation.

"No increases in plasma cytokine concentrations were seen following either polymer or carbon filtration techniques, supporting the conclusion that hemoperfusion did not incite an inflammatory response in the study population," the authors wrote.

Heparin doses exceeded equine requirements

Goats needed more anticoagulation than horses to keep blood moving through the circuit. An activated clotting time target of 700 to 900 seconds was required for consistent blood flow.

"Increasing the initial target ACT to 700 to 800 seconds required a starting bolus of up to double the UFH required in horses," the investigators reported, referring to unfractionated heparin. No clinical adverse effects of the higher doses were observed.

The practical point for clinicians: expect substantially higher heparin demands in goats than in equine extracorporeal protocols.

Study limitations and next steps

The authors noted that a larger sample size might have allowed a direct comparison of the two columns. The cost of therapy was not considered, and they cautioned that "a significant learning curve may be present for all extracorporeal therapies and hemoperfusion in particular."

The paper lists sepsis, intoxications, traumatic myositis, ischemia-reperfusion injury, hyperbilirubinemia, and liver disease as conditions for further investigation in goats. The Texas A&M team is also working to determine which substances the filter can remove most effectively.

The study was funded by an unrestricted grant from CytoSorbents USA, with research columns donated by AimaLojic. The study authors reported their findings in the American Journal of Veterinary Research (Bandyopadhyay S, Delvescovo B, Forbes J, Nelson T, Salakhov H, Hobbs K. Am J Vet Res. 2026;87(8. doi:10.2460/ajvr.26.03.0140).

With feasibility and safety now demonstrated in healthy animals, the work moves toward identifying which toxins and inflammatory mediators the columns remove most effectively in clinically ill goats.

Source: dvm360.com

Share this article:

Daniel Okafor

Show full bio

News editor covering technology and product news in Small- and large-animal clinical practice at The Vet Scope.

More from Daniel Okafor →